Table 5.

Relationship between risk of major osteoporotic fracture and FI and FRAX stratified by participants’ use of antiosteoporotic treatment, calcium and/or vitamin D supplementation.

Model	Major osteoporotic fracture^a
	Participants with antiosteoporotic treatment and/or supplementation (n = 2912)^b		Participants without antiosteoporotic treatment or supplementation (n = 1073)^c
	HR (95% CI)	p-Value	HR (95% CI)	p-Value
Models with per-0.01 increment
FRAX	1.03 (1.01–1.05)	<0.001	1.04 (1.01–1.08)	0.019
FI^d	1.02 (1.01–1.04)	0.001	1.02 (1.00–1.05)	0.033
Models with categorized groups
FRAX^e
Medium-risk
<365 days	1.54 (0.78–3.08)	0.22	0.92 (0.30–2.78)	0.87
365–550 days	1.52 (0.66–3.53)	0.33	0.62 (0.12–3.29)	0.58
>550 days	1.89 (0.98–3.65)	0.051	2.35 (0.64–8.64)	0.20
High-risk
<365 days	1.97 (0.76–5.11)	0.17	1.26 (0.26–6.03)	0.77
365–550 days	1.94 (0.84–4.48)	0.12	0.86 (0.16–4.83)	0.87
>550 days	2.42 (1.25–4.71)	0.009	3.26 (1.10–9.67)	0.034
FI^d,^f
Medium-risk	1.21 (0.76–1.93)	0.43	1.29 (0.58–2.88)	0.54
High-risk	2.00 (1.24–3.23)	0.004	2.14 (1.03–4.45)	0.041

HR: hazard ratio; CI: confidence interval; FRAX: fracture risk assessment tool; FI: frailty index.

Hip, upper arm or shoulder, spine, or wrist.

There were 108 incident major osteoporotic fracture reported.

There were 41 incident major osteoporotic fracture reported.

Adjusted for age.

Low-risk group taken as reference group; the cut-points were 10% and 20% for major osteoporotic fracture, while the cut-point was 3% for hip fracture; comparisons of high-risk versus low-risk and medium-risk versus low-risk group were within the same follow-up duration strata.

Low-risk group taken as reference group; the cut-points were 0.20 and 0.35 for major osteoporotic fracture, while the cut-point was 0.22 for hip fracture; comparisons of high-risk versus low-risk and medium-risk versus low-risk group were within the same follow-up duration strata.